

**Editor**

Tore K Kvien

**Associate Editors**

Francis Berenbaum  
Johannes Bijlsma  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes  
David Pisetsky

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 12.384

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2017 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 473** Importance of 'meeting of the minds': patient-reported outcomes and MRI  
*V K Ranganath, V Strand*

**Recommendations**

- 476** EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome  
*L Andreoli, G K Bertsias, N Agmon-Levin, S Brown, R Cervera, N Cosedoa-Chalumeau, A Doria, R Fischer-Betz, F Forger, M F Moraes-Fontes, M Khamashita, J King, A Lojaccono, F Marchiori, P L Meroni, M Mosca, M Motta, M Ostensen, C Pamfil, Z L Raio, M Schneider, E Svenungsson, M Tektonidou, S Yavuz, D Boumpas, A Tincani*

**Clinical and epidemiological research**

- 486** Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis  
*J F Baker, P G Conaghan, P Emery, D G Baker, M Ostergaard*
- 491** EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis  
*H W van Steenberg, D Aletaha, L J J Beart-van de Voorde, E Brouwer, C Codreanu, B Combe, J E Fonseca, M L Hetland, F Humby, T K Kvien, K Niedermann, L Nuño, S Oliver, S Rantapää-Dahlqvist, K Raza, D van Schaardenburg, G Scheit, L De Smet, G Szücs, J Vencovsky, P Wiland, M de Wit, R L Landewé, A H M van der Helm-van Mil*
- 497** Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis  
*L K Mercer, J B Galloway, M Lunt, R Davies, A L S Low, W G Dixon, K D Watson, BSRBR Control Centre Consortium, D P M Symmons, K L Hyrich*
- 504** Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs  
*A Strangfeld, A Richter, B Siegmund, P Herzer, K Rockwitz, W Demary, M Aringer, Y Meißner, A Zink, J Listing*
- 511** Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial  
*P Verschueren, D De Cock, L Corluy, R Joos, C Langenaken, V Taelman, F Raeman, I Ravelingien, K Vandevyvere, J Lenaerts, E Geens, P Geusens, J Vanhoof, A Durnez, J Remans, B V Cruyssen, E Van Essche, A Sileghem, G De Brabanter, J Joly, S Meyfroidt, K Van der Elst, R Westhovens*
- 521** Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis  
*S M Thorarensen, N Lu, A Ogdie, J M Gelfand, H K Choi, T J Love*
- 526** A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab  
*P Kaur, V Chow, N Zhang, M Moxness, A Kaliyaperumal, R Markus*
- 534** Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial  
*D J Wallace, V Strand, J T Merrill, S Popa, A J Spindler, A Eimon, M Petri, J S Smolen, J Wajdula, J Christensen, C Li, A Diehl, M S Vincent, J Beebe, P Healey, S Sridharan*
- 543** Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis  
*E M Miloslavsky, R P Naden, J W J Bijlsma, P A Brogan, E S Brown, P Brunetta, F Buttgerit, H K Choi, J-F DiCaire, J M Gelfand, L G Heaney, L Lightstone, N Lu, D F Murrell, M Petri, J T Rosenbaum, K S Saag, M B Urowitz, K L Winthrop, J H Stone*

**MORE CONTENTS ►**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.  
See <http://authors.bmj.com/open-access/>



Member since 2008

JMS00009

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it



The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 547** Remission in systemic lupus erythematosus: durable remission is rare  
*T R Wilhelm, L S Magder, M Petri*
- 554** A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)  
*R van Vollenhoven, A Voskuyl, G Bertias, C Aranow, M Aringer, L Arnaud, A Askanase, P Balázová, E Bonfa, H Bootsma, D Boumpas, I Bruce, R Cervera, A Clarke, C Coney, N Costedoat-Chalumeau, L Czirják, R Derksen, A Doria, T Dörner, R Fischer-Betz, R Fritsch-Stork, C Gordon, W Graninger, N Györi, F Houssiau, D Isenberg, S Jacobsen, D Jayne, A Kuhni, V Le Guern, K Lerström, R Levy, F Machado-Ribeiro, X Mariette, J Missaykeh, E Morand, M Mosca, M Inanc, S Navarra, I Neumann, M Olesinska, M Petri, A Rahman, O P Rekvig, J Rovensky, Y Shoenfeld, J Smolen, A Tincani, M Urowitz, B van Leeuw, C Vasconcelos, A Voss, V P Werth, H Zakharova, A Zoma, M Schneider, M Ward*
- 562** The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients  
*M Zen, L Iaccarino, M Gatto, S Bettio, F Saccon, A Ghirardello, L Punzi, A Doria*
- 566** A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis  
*D H Yoo, C-H Suh, S C Shim, S Jeka, F F Cons-Molina, P Hrycaj, P Wiland, E Y Lee, F G Medina-Rodriguez, P Shesternya, S Radominski, M Stanislav, V Kovalenko, D H Sheen, L Myasoutova, M J Lim, J-Y Choe, S J Lee, S Y Lee, T S Kwon, W Park*
- 571** Secukinumab efficacy in anti-TNF-naïve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study  
*J Sieper, A Deodhar, H Marzo-Ortega, J A Aelion, R Blanco, T Jui-Cheng, M Andersson, B Porter, H B Richards, on behalf of the MEASURE 2 Study Group*
- 593** Position 97 of HLA-B, a residue implicated in pathogenesis of ankylosing spondylitis, plays a key role in cell surface free heavy chain expression  
*L Chen, H Shi, J Yuan, P Bowness*
- 602** Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity  
*C K Smith, N L Seto, A Vivekanandan-Giri, W Yuan, M P Playford, Z Manna, S A Hasni, R Kuai, N N Mehta, A Schwendeman, S Pennathur, M J Kaplan*
- 612** Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression  
*E A Ross, A J Naylor, J D O'Neil, T Crowley, M L Ridley, J Crowe, T Smallie, T J Tang, J D Turner, L V Norling, S Dominguez, H Perlman, N M Verrills, G Kollias, M P Vittek, A Filer, C D Buckley, J L Dean, A R Clark*
- 620** miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis  
*L Chen, M H Al-Mossawi, A Ridley, T Sekine, A Hammützsch, J de Wit, D Simone, H Shi, F Penkava, M Kurowska-Stolarska, I Pulyakhina, J C Knight, T J Kim, P Bowness*
- 625** Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome  
*A Charras, O D Konsta, C Le Dantec, C Bagacean, E K Kapsogeorgou, A G Tzioufas, J-O Pers, A Bordron, Y Renaudineau*

## Electronic pages

### Correspondence

- e5** HCV-associated cryoglobulinemia vasculitis: are its days numbered?  
*S Moiseev, P Novikov, N Mukhin*
- e6** Response to: Cryoglobulinemic vasculitis in the era of direct-acting antiviral drug  
*D Saadoun, P Cacoub*

### Correction

- 611** Erratum: *Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs*

## Basic and translational research

- 576** The intervertebral disc contains intrinsic circadian clocks that are regulated by age and cytokines and linked to degeneration  
*M Dudek, N Yang, J PD Ruckshanthi, J Williams, E Borysiewicz, P Wang, A Adamson, J Li, J F Bateman, M R White, R P Boot-Handford, J A Hoyland, Q-J Meng*
- 585** A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis  
*K De Wilde, A Martens, S Lambrecht, P Jacques, M B Drennan, K Debusschere, S Govindarajan, J Coudeny, E Verheugen, F Windels, L Catrysse, R Lories, D McGonagle, R Beyaert, G van Loo, D Elewaut*